熱門資訊> 正文
I-Mab的ADS售价为6500万美元
2025-08-01 20:13
- I-Mab (NASDAQ:IMAB) has priced a public offering of 33.3 million American Depositary Shares (ADSs) at $1.95 per ADS, raising about $65 million in gross proceeds.
- All shares are being sold by the company, and the offering is expected to close on August 5, 2025, pending usual conditions.
- I-Mab plans to use the funds—along with its current cash—to support ongoing clinical trials, including a Phase 2 study of givastomig, a bispecific antibody targeting Claudin 18.2 and 4-1BB, with results expected by late 2027. Proceeds will also go toward working capital and general corporate needs.
- Source: Press Release
More on I-Mab Biopharma
- I-Mab to buy Bridge Health to strengthen cancer drug development
- Seeking Alpha’s Quant Rating on I-Mab Biopharma
- Historical earnings data for I-Mab Biopharma
- Financial information for I-Mab Biopharma
推薦文章
飆漲60%創新高！英諾賽科官宣成英偉達供應商，機構喊話股價上行潛力仍然巨大
華盛早報丨黑天鵝來襲？特朗普掀起人事震動，美國對等關税生效在即；小米汽車7月交付量超3萬輛
港股周報丨中美經貿會談達成延長90天共識；京東、阿里、美團集體發文抵制外賣行業內卷
一周財經日曆 | 特朗普對等關税將於8月7日生效；Palantir、超微電腦等財報來襲
8月金股搶先睇！港股能否繼續抽升？哪些賽道值得關注
英諾賽科午前飆升逾31% 英偉達最新800V架構供應商名單曝光公司為中國唯一入選芯片企業
蘋果第三財季營收940.36億美元 淨利潤同比增長9%
外盤頭條：白宮稱特朗普將在午夜前設定新關税 蘋果季度營收遠超預期 Pimco青睞短至中期歐洲債券
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
